Percentage of apoptotic HT29 cells after third schedule administration as identified by three different techniques
| Treatment | Sub-G1 peak | PI supravital exposure | Morphology | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 h | 24 ha | 0 h | 24 h | 0 h | 24 h | ||||
| Control | 0.6b | 0.6 | 1 | 1 | 1.6 | 1 | |||
| 1 nm TAX | 0 | 0.6 | 0 | 1 | NDc | ND | |||
| 5 nm TAX | 0 | 2 | 0 | 2 | ND | ND | |||
| 10 nm TAX | 0 | 8 | 0 | 10 | ND | 5 | |||
| 3 × 2 Gy | 5 | 5 | 7 | 6 | 3 | 3 | |||
| 1 nm + 3 × 2 Gy | 9 | 6 | 11 | 6 | ND | ND | |||
| 5 nm + 3 × 2 Gy | 13 | 8 | 12 | 7 | ND | ND | |||
| 10 nm + 3 × 2 Gy | 22 | 15 | 20 | 10 | 15 | 8 | |||
| Sodium azide, 0.1% | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Dexamethasone, 100 nm | 8 | ND | 7 | ND | 6 | ND | |||
a 24 h drug-free medium.
b Data represent mean values from three separate experiments; SD, <5%.
c ND, not determined.